Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer

Inclusion Criteria:

* Ability to understand and willingness to sign an IRB-approved informed consent
* Age ≥50 years at the time of enrollment
* Newly diagnosed or suspected FIGO Stage II-IV ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype OR FIGO Stage II-IV endometrial carcinoma of any histological subtype
* Planned, standard of care treatment consisting of neoadjuvant chemotherapy, tumor reduction surgery, and adjuvant chemotherapy OR tumor reduction surgery with adjuvant chemotherapy
* Ability to read and understand the English language

Exclusion Criteria:

* Previously treated for ovarian or endometrial cancer
* History of brain metastases, whole brain irradiation, poorly controlled psychiatric disorders defined by hospitalization within the last 3 months for psychiatric diagnoses, traumatic brain injury, cerebrovascular event, or dementia
* Currently taking anti-amyloid agents, cholinesterase inhibitors, or glutamate regulator
* Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study